Artboard 1.png

MirZyme Therapeutics is focused on the development and commercialisation of targeted therapeutics to prevent preeclampsia. 


MirZyme has several global patents granted. These relate to a pipeline of product offerings that address the unmet medical needs of patients with preeclampsia. Uniquely, MirZyme will be the first to provide targeted therapeutics with a companion diagnostic test for the disorder.

Professor Ahmed holds the position of Executive Chairman of the Board and oversees the vision and direction of the company. He has hand selected a great team to work within MirZyme, and collectively, they are developing a cure for preeclampsia.

"Out of clutter find simplicity; From discord find harmony; In the middle of difficulty lies opportunity."
~Albert Einstein

Solving the problem

Professor Ahmed's team at MirZyme is working towards developing and commercialising diagnostics and drugs to prevent pregnancy complications, in particular preeclampsia and fetal growth restriction.